Based on the outstanding results reported by the VISION trial concerning the administration of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer [11], it is feasible that tumors characterized by PSMA expression (even if in the neovasculature instead of on the cancer cells) might present a satisfactory response to this therapy. The gene discussed is FOLH1; the disease is cancer.